Pharmacogenomics in gastrointestinal disorders

Methods in Molecular Biology

Volumn 448, Issue , 2008, Pages 395-412

  Camilleri, Michael ^a   Saito, Yuri A ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

Colon cancer; Functional dyspepsia; Functional gastrointestinal disorders; Gastroesophageal reflux disease; Helicobacter pylori infection; Inflammatory bowel disease; Irritable bowel syndrome; Liver transplantation; Pharmacogenetics

Indexed keywords

HELICOBACTER; HELICOBACTER PYLORI;

EID: 84934436321     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-205-2_13     Document Type: Article

References (94)

1. Roden, D. M., Altman, R. B., Benowitz, N. L., et al. (2006) Pharmacogenomics: challenges and opportunities. Ann. Intern. Med. 145, 749-257.
2. Locke, G. R., III, Taller, N. J., Fett, S. L., Zinsmeister, A. R., and Melton, L. J., III. (1997) Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 112, 1448-1456.
3. Kurata, J. H., and Nogawa, A. N. (1997) Meta-analysis of risk factors for peptic ulcer. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and smoking. J. Clin. Gastroenterol. 24, 2-17.
4. Pounder, R. E., and Ng, D. (1995) The prevalence of Helicobacter pylori infection in different countries. Aliment. Pharmacol. Ther. 9, 33-39.
5. Marshall, B. J., Goodwin, C. S., Warren, J. R., et al. (1988) Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 2, 1437-1442.
6. Rauws, E. A., and Tytgat, G. N. (1990) Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 335, 1233-1235.
7. Howden, C. W., Henning, J. M., Huang, B., Lukasik, N., and Freston, J. W. (2001) Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am. J. Gastroenterol. 96, 1704-1710.
8. Van Zyl, J., Van Rensburg, C., Vieweg, W., and Fischer, R. (2004) Efficacy and safety of pantoprazole vs ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease. Digestion. 70, 61-69.
9. Farley, A., Wruble, L. D., and Humphries, T. J. (2000) Rabeprazole vs ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. Am. J. Gastroenterol. 95, 1894-1899.
10. Richter, J. E., Campbell, D. R., Kahrilas, P. J., Huang, B., and Fludas, C. (2000) Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch. Intern. Med. 160, 1803-1809.
11. Klotz, U., Schwab, M., and Treiber, G. (2004) CYP2C19 polymorphism and proton pump inhibitors. Basic Clin. Pharmacol. Toxicol. 95, 2-8.
12. Kita, T., Sakaeda, T., Baba, T., et al. (2003) Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol. Pharm. Bull. 26, 386-390.
13. Ishizaki, T., and Horai, Y. (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment. Pharmacol. Ther. 13, 27-36.
14. Shimatani, T., Inoue, M., Kuroiwa, T., et al. (2006) Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin. Pharmacol. Ther. 79, 144-152.
15. De Morais, S. M., Wilkinson, G. R., Blaisdell, J., et al. (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 15419-15422.
16. De Morais, S.M., Wilkinson, G.R., Blaisdell, J., et al. (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46, 594-598.
17. Ferguson, R. J., De Morais, S. M., Benhamou, S., et al. (1998) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther. 284, 356-361.
18. Ibeanu, G. C., Blaisdell, J., Ghanayem, B. I., et al. (1998) An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics. 8, 129-135.
19. Blaisdell, J., Mohrenweiser, H., Jackson, J., et al. (2002) Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics. 12, 703-711.
20. OMIM record *124020. Available at www.ncbi.nlm.nih.gov.
21. Furuta, T., Shirai, N., Watanabe, F., et al. (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin. Pharmacol. Ther. 72, 453-460.
22. Kawamura, M., Ohara, S., Koike, T., et al. (2003) The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment. Pharmacol. Ther. 17, 965-973.
23. Chong, E., and Ensom, M. H. (2003) Pharmacogenetics. of the proton pump inhibitors: a systematic review. Pharmacotherapy. 23, 460-471.
24. Schwab, M., Schaeffeler, E., Klotz, U., and Treiber, G. (2004) CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin. Pharmacol. Ther. 76, 201-209.
25. Juran, B., Egan, L., and Lazaridis, K. (2006) The AmpliChip CYP450 test: principles, challenges, and future clinical utility in digestive disease. Clin. Gastroenterol. Hepatol. 4, 822-830.
26. Loftus, E. V., Jr. (2004) Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 126, 1504-1517.
27. Ahmad, T., Satsangi, J., McGovern, D., Bunce, M., and Jewell, D. P. (2001) Review article: the genetics of inflammatory bowel disease. Aliment. Pharmacol. Ther. 15, 731-748.
28. Colombel, J. F. (2003) The CARD15 (also known as NOD2) gene in Crohn's disease: are there implications for current clinical practice? Clin. Gastroenterol. Hepatol. 1, 5-9.
29. Dubinsky, M. C. (2004) Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin. Gastroenterol. Hepatol. 2, 731-743.
30. Su, C., and Lichtenstein, G. R. (2004) Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol. Clin. North Am. 33, 209-234.
31. Tai, H. L., Krynetski, E. Y., Schuetz, E. G., Yanishevski, Y., and Evans, W. E. (1997) Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. U. S. A, 94, 6444-6449.
32. Roberts, R. L., Barclay, M. L., Gearry, R. B., and Kennedy, M. A. (2004) A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) muta tions. Clin. Chim. Acta. 341, 49-53.
33. Weinshilboun, R.M., and Sladek, S. L. (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651-662.
34. Winter, J., Walker, A., Shapiro, D., et al. (2004) Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 20, 593-599.
35. Colombel, J. F., Ferrari, N., Debuysere, H., et al. (2000) Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 118, 1025-1030.
36. De Ridder, L., Van Dieren, J. M., Van Deventer, H. J., et al. (2006) Pharmacogenetics. of thiopurine therapy in paediatric IBD patients. Aliment. Pharmacol. Ther. 23, 1137-1141.
37. Derijks, L. J., Gilissen, L. P., Engels, L. G, et al. (2004) Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther. Drug Monit. 26, 311-318.
38. Dubinsky, M. C., Yang, H., Hassard, P. V., et al. (2002) 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 122, 904-915.
39. Ansari, A., Hassan, C., Duley, J., et al. (2002) Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment. Pharmacol. Ther. 16, 1743-1750.
40. Sumi, S., Marinaki, A. M., Arenas, M., et al. (2002) Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum. Genet. 111, 360-367.
41. Marinaki, A. M., Ansari, A., Duley, J. A., et al. (2004) Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics. 14, 181-187.
42. Gearry, R. B., Roberts, R. L., Barclay, M. L., and Kennedy, M. A. (2004) Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics. 14, 779-781.
43. Allorge, D., Hamdan, R., Broly, F., Libersa, C., and Colombel, J. F. (2005) ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut. 54, 565-568.
44. Van Dieren, J. M., Van Vuuren, A. J, Kusters, J. G, et al. (2005) ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut. 54, 1664.
45. Zelinkova, Z., Derijks, L. J., Stokkers, P. C., et al. (2006) Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin. Gastroenterol. Hepatol. 4, 44-49.
46. Ricart, E., Taylor, W. R., Loftus, E. V., et al. (2002) N-Acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am. J. Gastroenterol. 97, 1763-1768.
47. Shetty, A., and Forbes, A. (2002) Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease. Am. J. Pharmacogenomics. 2, 215-221.
48. Louis, E., Vermeire, S., Rutgeerts, P., et al. (2002) A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand. J. Gastroenterol. 37, 818-824.
49. Mascheretti, S., Hampe, J., Kuhbacher, T., et al. (2002) Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J. 2, 127-136.
50. Hlavaty, T., Pierik, M., Henckaerts, L., et al. (2005) Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 22, 613-626.
51. Dideberg, V., Theatre, E., Farnir, F., et al. (2006) The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet. Genomics. 16, 727-734.
52. Mascheretti, S., Hampe, J., Croucher, P. J., et al. (2002) Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Pharmacogenetics. 12, 509-515.
53. Vermeire, S., Louis, E., Rutgeerts, P., et al. (2002) NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology. 123, 106-111.
54. Saito, Y. A., Schoenfeld, P., and Locke, G. R., III. (2002) The epidemiology of irritable bowel syndrome in North America: a systematic review. Am. J. Gastroenterol. 97, 1910-1915.
55. Kozma, C. M., Barghout, V., Slaton, T., Frech, F., and Reeder, C.E. (2002) A comparison of office-based physician visits for irritable bowel syndrome and for migraine and asthma. Manag. Care Interface. 15, 40-43, 49.
56. Drossman, D. A., Camilleri, M., Mayer, E. A., and Whitehead, W. E. (2002) AGA technical review on irritable bowel syndrome. Gastroenterology. 123, 2108-2131.
57. Gershon, M. D. (2004) Review article: serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment. Pharmacol. Ther. 20, 3-14.
58. Viramontes, B. E., Camilleri, M., McKinzie, S., Pardi, D. S., Burton, D., and Thomforde, G. M. (2001) Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 96, 2671-2676.
59. Chen, J. J., Li, Z., Pan, H., et al. (2001) Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J. Neurosci. 21, 6348-6361.
60. Lesch, K. P, Balling, U., Gross, J., et al. (1994) Organization of the human serotonin transporter gene. J. Neural Transm. Gen. Sect. 95, 157-162.
61. Lesch, K. P., Bengel, D., Heils, A., et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 274, 1527-1531.
62. Yeo, A., Boyd, P., Lumsden, S., et al. (2004) Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut. 53, 1452-1458.
63. Camilleri, M., Atanasova, E., Carlson, P. J., et al. (2002) Serotonin-transporter polymorphism. Pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology. 123, 425-432.
64. Li, Y. Y., Nie, Y. Q., Xie, J., Tan, H. Z., Zhou, Y. J., and Wang, H. (2006) Serotonin transporter gene polymorphisms in irritable bowel syndrome and their impact on tegaserod treatment. Zhonghua Nei Ke Za Zhi. 45, 552-555.
65. Organ procurement and transplantation notebook. Available at: www.optn.org.
66. OMIM record *124010. Available at: www.ncbi.nlm.nih.gov.
67. Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J., and Malkowicz, S. B. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 90, 1225-1229.
68. Amirimani, B., Ning, B., Deitz, A. C., et al. (2003) Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen. 42, 299-305.
69. Hesselink, D. A., Van Schaik, R. H., Van der Heiden, I. P., et al. (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74, 245-254.
70. Hesselink, D. A., Van Gelder, T., Van Schaik, R. H., et al. (2004) Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther. 76, 545-556.
71. Kuehl, P., Zhang, J., Lin, Y., et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391.
72. Zhao, Y., Song, M., Guan, D., et al. (2005) Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant. Proc. 37, 178-181.
73. Thiebaut, F., Tsuruo, T., Hamada, H., et al. (1987) Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U. S. A. 84, 7735-7738.
74. Hoffmeyer, S., Burk, O., Von Richter, O., et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 97, 3473-3478.
75. Bonhomme-Faivre, L., Devocelle, A., Saliba, F., et al. (2004) MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation. 78, 21-25.
76. Jin, J., Wu, L.H., Wang, W.L., et al. (2005) Impact of multidrug resistance 1 gene polymorphism on tacrolimus dose and concentration-to-dose ratio in Chinese liver transplantation recipients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 22, 616-620.
77. Centers for Disease Control and Prevention Web site. Available at: www.cdc.gov.
78. Parkin, D. M., Pisani, P., and Ferlay, J. (1999) Global cancer statistics. CA. Cancer J. Clin. 49, 31-64.
79. Moore, H. C., and Haller, D. G. (1999) Adjuvant therapy of colon cancer. Semin. Oncol. 26, 545-555.
80. Stewart, J. M., and Zalcberg, J. R. (1998) Update on adjuvant treatment of colorectal cancer. Curr. Opin. Oncol. 10, 367-374.
81. Salonga, D., Danenberg, K. D., Johnson, M., et al. (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6, 1322-1327.
82. Milano, G., Etienne, M. C., Pierrefite, V., et al. (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer. 79, 627-630.
83. Wei, X., McLeod, H. L., McMurrough, J., Gonzalez, F. J., and Fernandez-Salguero, P. (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98, 610-615.
84. Ridge, S. A., Sludden, J., Brown, O., et al. (1998) Dihydropyrimidine dehydrogenase Pharmacogenetics. in Caucasian subjects. Br. J. Clin. Pharmacol. 46, 151-156.
85. Horie, N., Aiba, H., Oguro, K., Hojo, H., and Takeishi, K. (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5 -terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20, 191-197.
86. Kawakami, K., Omura, K., Kanehira, E., and Watanabe, Y. (1999) Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 19, 3249-3252.
87. Popat, S., Matakidou, A., and Houlston, R. S. (2004) Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J. Clin. Oncol. 22, 529-536.
88. Ando, Y., Saka, H., Ando, M., et al. (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926.
89. Iyer, L., Das, S., Janisch, L., et al. (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2, 43-47.
90. Han, J. Y., Lim, H. S., Shin, E. S., et al. (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24, 2237-2244.
91. Egan, L. J., Derijks, L. J., and Hommes, D. W. (2006) Pharmacogenomics in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4, 21-28.
92. Food and Drug Administration. FDA clears genetic test that advances personalized medicine. Test helps determine safety of drug therapy. Available at: http://www.fda.gov/bbs/topics/NEWS/2005/NEW01220.html. Accessed July 27, 2006.
93. Stoehlmacher, J., Park, D. J., Zhang, W., et al. (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl. Cancer Inst. 94, 936-942.
94. Lu, Y., Kow-Yin Kham, S., Foo, T. C., Hany, A., Quah, T. C. and Eng-Juh Yeoh, A. (2006, October 26) Genotyping of eight polymorphic genes encoding drug-metabolizing enzymes and transporters using a customized oligonucleotide array. Anal. Biochem. Epub ahead of print.